Targeting RAS–ERK signalling in cancer: promises and challenges
The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Abstract
The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes. Recently, the use of compounds targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clinical outcome in metastatic melanoma and has shown promising clinical activity in additional tumour types. However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance. Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently associated with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The activity of single agent therapies targeting individual RAS effector pathways is limited”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“combinations of inhibitors targeting multiple effector and/or feedback pathways have shown impressive activity in KRAS mutant model systems”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“Determinants of primary resistance are not the same in different tumor types that up-regulate various RTKs or their ligands in response to pathway inhibition (111-113).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [113]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Cited by
Items 901–1,000 of 1,000
Rational design of dual ALK inhibitors: scaffolds and strategies to circumvent drug resistance
Yahya, T. A. A., & Al-Qadhi, M. A. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109706 · Cited by 2
New understanding of the molecular pathogenesis and therapeutic progress of hepatocellular carcinoma
Wang, W.-J., Yuan, H.-X., Xu, J.-Z., Wang, X.-D., Na, G.-W., He, K.-J., Sun, W., Li, R., Che, J., & Cheng, Y.-S. (2026) · Oncology Reviews · doi:10.3389/or.2026.1763632 · Cited by 2
Hong, J., Zheng, W., & Cai, X. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220830145026 · Cited by 3
Low Pi stress enhances the sensitivity of hepatocellular carcinoma to sorafenib
Bi, Q., Deng, Z.-Q., Lv, Y., Liu, Y., Xie, C.-S., He, Y., & Tang, Q. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115593 · Cited by 2
Sahu, P., Mitra, A., & Ganguly, A. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.01.005 · Cited by 2
Zeng, Y., Huang, C., Hou, Q., Jiang, W., Cheng, J., & Wu, X. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107833 · Cited by 3
Susianti, S., Bahri, S., Hadi, S., Setiawansyah, A., Rachmadi, L., Fadilah, I., & Ratna, M. G. (2024) · Journal of Multidisciplinary Applied Natural Science · doi:10.47352/jmans.2774-3047.228 · Cited by 5
Osteosarcoma cells‐derived exosomal YES1 promote tumor progression via MAPK pathway
Li, Z., Chen, Q., Zhang, Y., Ye, Z., Song, Y., Zhang, Y., Gu, C., Jia, T., Yang, Y., & Shang, A. (2025) · Interdisciplinary medicine · doi:10.1002/inmd.20240072 · Cited by 4
MUC3A promotes the progression of cholangiocarcinoma through the MAPK/ERK pathway
Feng, B., Su, W., Hu, L., & Yu, M. (2025) · Discover Oncology · doi:10.1007/s12672-025-02199-7 · Cited by 2
Luo, P., Liu, Y., Xu, L., Liu, Z., Wang, L., Wong, H. Z. H., Cheng, Q., Lin, A., Fang, X., & Jiang, A. (2025) · View · doi:10.1002/viw.20240113 · Cited by 2
Proteomics equipped with multiplexing toward ultra high throughput
Kim, M. (2014) · PROTEOMICS · doi:10.1002/pmic.201400593 · Cited by 2
Integrating genomic information and signaling dynamics for efficient cancer therapy
Stewart-Ornstein, J., & Lahav, G. (2016) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2016.12.013 · Cited by 2
Emerging Therapeutic Targets in Pancreatic Adenocarcinoma
Choe, J. H., & Abbruzzese, J. L. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_92-1 · Cited by 2
Grabenbauer, F., Katzer, A., Sisario, D., Memmel, S., Flentje, M. P., Sukhorukov, V. L., & Djuzenova, C. S. (2018) · Oncotarget · doi:10.18632/oncotarget.26436 · Cited by 4
AXL Downstream Targeting Unravels Synergistic Drug Combinations in Ovarian Carcinoma Cells
ALAMPI, D. M., Ciusani, E., Carenini, N., Corna, E., Gatti, L., & Corno, C. (2019) · Anticancer Research · doi:10.21873/anticanres.13529 · Cited by 2
Chemical engineering of bacterial effectors for regulating cell signaling and responses
Yang, S., Ngai, W. S. C., & Chen, P. R. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.04.003 · Cited by 2
Emerging Therapeutic Targets in Pancreatic Adenocarcinoma
Choe, J. H., & Abbruzzese, J. L. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_92 · Cited by 2
Ünver, N., Tavukçuoğlu, E., & Esendağlı, G. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121171 · Cited by 2
Li, W., Shao, L., Liu, J., Sheng, J., Zheng, Q., & Wang, M. (2023) · Biomaterials Science · doi:10.1039/d3bm00008g · Cited by 2
New Challenges in Cancer Therapy: MAPK Inhibitors from Bench to Bedside
Ropert, C., & Huth, H. W. (2017) · Springer eBooks · doi:10.1007/978-3-319-53082-6_3 · Cited by 1
Promising Molecular Targets for Design of Antitumor Drugs Based on Ras Protein Signaling Cascades
Klochkov, S. G., Неганова, М. Е., & Aleksandrova, Y. R. (2020) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162020050118 · Cited by 2
Autophagy in the Immunosuppressive Perivascular Microenvironment of Glioblastoma
Molina, M. L., García‐Bernal, D., Martínez, S., & Valdor, R. (2020) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pacr.1.2020.18 · Cited by 2
Treatments That Block Proteins Involved in Cell Communication
PhD, E. V. (2018) · Wiley eBooks · doi:10.1002/9781119126843.ch3 · Cited by 2
Protomer Selectivity of RAF Inhibitors Within the RAS/RAF SignalosomePreprint
Vasta, J. D., Michaud, A., Zimprich, C., Thomas, M., Wilkinson, J., Crapster, J. A., & Robers, M. B. (2022) · Research Square · doi:10.21203/rs.3.rs-2175742/v1 · Cited by 2
Photoswitchable binders enable temporal dissection of endogenous protein functionPreprint
Westberg, M., Song, D., Duong, V. T., Fernández, D., Huang, P., & Lin, M. Z. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.14.557687 · Cited by 2
Mechanism of dimer selectivity and binding cooperativity of BRAF inhibitorsPreprint
Clayton, J., Romany, A., Matenoglou, E., Gavathiotis, E., Poulikakos, P. I., & Shen, J. (2024) · eLife · doi:10.7554/elife.95334 · Cited by 2
Self-citationRAS mutation-specific signaling dynamics in response to paralog- and state- selective RAS inhibitorsPreprint
Baars, B., Orive-Ramos, A., Kou, Z., Gaire, B., Desaunay, M., Adamopoulos, C., Aaronson, S. A., Wang, S., Gavathiotis, E., & Poulikakos, P. I. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.14.638317 · Cited by 2
Self-citationHirota, A., Clément, J.-E., Tanikawa, S., Nonoyama, T., Komatsuzaki, T., Gong, J. P., Tanaka, S., & Imajo, M. (2022) · Cancers · doi:10.3390/cancers14235890 · Cited by 2
Li, H., Ye, Z., Wang, X., Yuan, J., Guo, J., Liu, C., Yan, B., Fan, H., Lyu, Y., & Liu, X. (2024) · iScience · doi:10.1016/j.isci.2024.110029 · Cited by 1
Effectiveness and Mechanism of Resibufogenin on Human Renal Cancer Cell Caki-1
Wu, Y., Yang, Y., Huang, R., Li, T., Wan, C., & Zhang, L. (2024) · Biology · doi:10.3390/biology13121064 · Cited by 1
MYC Overexpression Enhances Sensitivity to MEK Inhibition in Head and Neck Squamous Cell Carcinoma
Yang, C., Pang, X., Teng, S., Wilson, S., Gu, X., & Xie, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020588 · Cited by 1
The paradoxical activity of BRAF inhibitors: potential use in wound healing
Karhana, S., Samim, M., Nidhi, & Khan, M. A. (2025) · Archives of Dermatological Research · doi:10.1007/s00403-024-03785-5 · Cited by 1
Clinicopathological features and BRAFV600E mutation analysis in colorectal cancer
Thomas, N., Pai, U. K. N., Raju, L., Suresh Kumar, R., & Ragitha, T. S. (2025) · Asian Journal of Oncology · doi:10.25259/asjo_60_2024 · Cited by 1
Zhang, P., Zhang, Y., Sun, Y., Chen, Y., Cao, X. M., He, Y., Tan, Y., Zhang, Z., Deng, S., Zhou, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01055 · Cited by 1
Panagi, M., Γαλάρας, Α., Hatzis, P., & Apidianakis, Y. (2025) · Biology Open · doi:10.1242/bio.061960 · Cited by 2
Huang, S., Chen, Y., Hu, M., Fu, S., Yao, Z., He, H., Wang, L., Chen, Z., & Liu, X. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104860 · Cited by 2
Wei, J., Liu, J., Zhang, Y., Wang, G., Cui, X., Yu, W., Nie, C., & Hou, P. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.111224 · Cited by 1
Zampieri, C., Kouhmareh, K., Sartipdolagh, P., Azmoon, P., Klemke, R. L., & Gonias, S. L. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110561 · Cited by 3
Yang, J., Qiao, Q., Lin, N., Niu, M., Su, L., & Yin, B. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70427 · Cited by 2
Zhou, J., Fang, Z., Zhang, W., Rao, G.-W., & Zheng, Q. (2025) · Mini-Reviews in Organic Chemistry · doi:10.2174/0118756298391640250731025705 · Cited by 1
The dynamics of ubiquitination and its role within the proteome of extracellular vesicles
Morales-Tarré, O., Popa-Navarro, X., Paradela, A., Hernández‐Ortíz, M., Arrieta, O. G., Corrales, F. J., & Encarnación‐Guevara, S. (2025) · Journal of Proteomics · doi:10.1016/j.jprot.2025.105566 · Cited by 3
The evolving landscape in neurofibromatosis type 1: promise under pressure
Huang, J., Liu, J., Li, Y., Yu, X., Wang, Z., & Li, Q. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003724 · Cited by 1
Pancreatic cancer: emerging small molecule pharmacotherapies
Pokora, B., Pokora, K., & Fichna, J. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2657995 · Cited by 1
Liu, L., 陈颖君, Guo, M., Yun, F., Li, X., Chen, L., Li, Y. M., & Li, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1782130 · Cited by 1
Mechanisms of Protein Homeostasis Regulation in Cancer Development
Trčka, F., Müller, P., & Vojtěšek, B. (2016) · Klinicka onkologie · doi:10.14735/amko20164s18 · Cited by 1
Genome-Wide Analysis of RAS/ERK Signaling Targets
Plotnik, J. P., & Hollenhorst, P. C. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6424-6_21 · Cited by 1
Hu, H., Zhang, T., Wu, Y., Deng, M., Deng, H., & Yang, X. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2101994 · Cited by 1
Role of Circular RNAs in Prostate Cancer
Chen, F., Zhang, F., Liu, Y., & Leng, Y. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230531095850 · Cited by 1
Martín-Bermudo, M. D., Millán, A. M.-A., Beatty, J. S., & Valencia-Expósito, A. (2023) · Genes · doi:10.3390/genes14071502 · Cited by 1
Braissand, N., & Coste, I. (2023) · médecine/sciences · doi:10.1051/medsci/2023126 · Cited by 1
Yuan, Q., Shi, Y., Zhang, Y., Shi, Y., Hussain, Z., Zhao, J., Jiang, Y., Qiao, Y., Guo, Y., Lü, J., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03291-8 · Cited by 4
An updated patent review of SOS1 inhibitors (2022–present)
Zhou, G., Zhou, C., Ma, X., Xu, J., Zhou, Z., Xu, T., Zheng, M., & Zhang, S. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2419825 · Cited by 1
Khan, A. A., Ali, S. S., Zahid, M., Abdelsalam, S. S., Albekairi, N., Al‐Zoubi, R. M., Shkoor, M., Wei, D., & Agouni, A. (2024) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26759 · Cited by 1
Chu, W., & Wang, J. (2024) · The Journal of Chemical Physics · doi:10.1063/5.0238929 · Cited by 1
Moon, H., Park, H., Lee, S.-H., Lee, S., Jun, M., Lee, J., Baek, J., Park, H., Bang, J., & Ro, S. W. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101536 · Cited by 1
Ho, T. H., Sistonen, S. J., Koivusalo, A., Pakarinen, M. P., Rintala, R. J., Stenman, U., Orpana, A., Stenman, J. J. E., & Dang, K. X. (2017) · European Journal of Pediatric Surgery · doi:10.1055/s-0037-1605346 · Cited by 1
Arba, M., Ruslin, R., Nursan, N., Maulidiyah, M., & Tjahjono, D. H. (2018) · Jurnal Kimia VALENSI · doi:10.15408/jkv.v4i1.7454 · Cited by 5
Gao, X., Cheng, Z., Yuan, H., & Zhao, H. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29284 · Cited by 1
RetractedExploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook
Moschopoulou, A. A., Zwirner, S., Zender, L., & Dauch, D. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_100 · Cited by 2
Drosophila Cancer Modeling Using the Eye Imaginal Discs
Gangwani, K., Snigdha, K., Atkins, M., Singh, S. R., & Kango‐Singh, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-42246-2_9 · Cited by 2
Targeted therapy for advanced cutaneous melanoma
Indini, A., Roila, F., Gueli, R., Grossi, F., & Mandalà, M. (2022) · Oncology in Clinical Practice · doi:10.5603/ocp.2022.0005 · Cited by 1
Anoikis Regulation: Complexities, Distinctions, and Cell Differentiation
Beauséjour, M., Boutin, A., & Vachon, P. H. (2018) · Wiley eBooks · doi:10.1002/9781119432463.ch8 · Cited by 2
(2019) · BioFactors · doi:10.1002/biof.1589 · Cited by 1
RetractedCristinziano, G., Porru, M., Lamberti, D., Buglioni, S., Rollo, F., Amoreo, C. A., Manni, I., Giannarelli, D., Cristofoletti, C., Russo, G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.20.106104 · Cited by 1
Tian, P., Zhu, Y., Zhang, C., Guo, X., Zhang, P., & Xue, H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08340-3 · Cited by 1
RetractedUpregulation of SNTB1 Correlates with Poor Prognosis and Promotes Cell Growth in Colorectal CancerPreprint
Liu, L., Chen, Y., Lin, X., Wu, M., Li, J., Xie, Q., Sferra, T. J., Han, Y., Liu, H., Cao, L., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-549083/v1 · Cited by 1
Brummer, T. (2017) · Springer eBooks · doi:10.1007/978-3-662-46875-3_704 · Cited by 1
Mitogen-Activated Protein Kinases
Meloche, S. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_193-1 · Cited by 1
Mitogen-Activated Protein Kinases
Meloche, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_193 · Cited by 1
Nussbaum, D. P., Martz, C. A., Waters, A. M., Barrera, A., Rutter, J. C., Cerda-Smith, C. G., Stewart, A. E., Wu, C., Çakır, M., Levandowski, C. B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.17.508384 · Cited by 1
Sinularin stabilizes FOXO3 protein to trigger prostate cancer cell intrinsic apoptosisPreprint
Meng, X., Wang, K., Ye, S., Chen, J., Chen, Z.-Y., Zhang, Z., Li, Y., Yu, R., & Ma, Q. (2022) · Research Square · doi:10.21203/rs.3.rs-2091932/v1 · Cited by 1
Adamopoulos, C., Ahmed, T. A., Tucker, M. R., Ung, P. M. U., Xiao, M., Karoulia, Z., Amabile, A., Wu, X., Aaronson, S. A., Ang, C., et al. (2023) · doi:10.1158/2159-8290.c.6549364 · Cited by 1
Self-citationLu, W., Liu, L., Lin, X., Liu, H., Shen, A., Wei, L., Sferra, T. J., Chen, Y., & Li, L. (2023) · Research Square · doi:10.21203/rs.3.rs-3171194/v1 · Cited by 1
Mechanism of Dimer Selectivity and Binding Cooperativity of BRAF InhibitorsPreprint
Clayton, J., Romany, A., Matenoglou, E., Gavathiotis, E., Poulikakos, P. I., & Shen, J. (2025) · eLife · doi:10.7554/elife.95334.3 · Cited by 1
Self-citationTranslating Seminoma Genomic Landscapes into Clinical Practice
Gerlinger, M. (2015) · European Urology · doi:10.1016/j.eururo.2015.01.020
From epithelial to mesenchymal: regulation of invasive cancer cell motility
Virtakoivu, R. (2015) · UTUPub (University of Turku)
Emerging Molecular Targets in the Treatment of Head and Neck Squamous Cell Carcinoma
Warner, B. M., & Grandis, J. R. (2016) · Springer eBooks · doi:10.1007/978-3-319-27647-2_8
Fortschritte bei der Ras‐Inhibition aus medizinisch‐chemischer Perspektive
Sautier, B., Nising, C. F., & Wortmann, L. (2016) · Angewandte Chemie · doi:10.1002/ange.201608270
The Dawning of Translational Breast Cancer: From Bench to Bedside
Chen, X., Fan, S., & Song, E. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_1 · Cited by 1
Principles of Targeted Therapy
Bollag, G. E., & Flaherty, K. T. (2018) · Springer eBooks · doi:10.1007/978-1-4614-7322-0_35-1
Translational Research and Genomics Driven Trials in Thyroid Cancer
Cabanillas, M. E., Schweppe, R. E., Dadu, R., Cote, G. J., Beadnell, T. C., & Hofmann, M.-C. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-91725-2_24
ENHANCING RADIATION SENSITIVITY IN NON-SMALL CELL LUNG CANCER
Wang, Y. (2018) · Digital Commons-TMC (Texas Medical Center)
Wang, G., Wang, J., Yin, P., Xu, K., Wang, Y., Shi, F., Gao, J., & Fu, X. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27558
Automating Gene Editing Using Digital Microfluidics to Decipher Cancer Pathways
Sinha, H. (2018) · Spectrum Research Repository (Concordia University)
Targeted Therapies for BRAF-Mutant Metastatic Melanoma
Johnson, D. B., Dummer, R., Flaherty, K. T., & Smalley, K. S. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-46029-1_40-1
Baker, N. M. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/vf3z-jk38 · Cited by 1
Molecular Biomarkers for the Management of Colorectal Cancer Liver Metastases
Squires, M. H., Cloyd, J. M., & Pawlik, T. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-25486-5_3
SREBP1 regulates mitochondrial metabolism in oncogenic KRAS expressing NSCLCPreprint
Ruiz, C. F., Montal, E. D., Haley, J. D., & Haley, J. D. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.15.896373 · Cited by 1
A Novel Function of Myc-nick, a Cleavage Product of c-Myc, in Resolution of Inflammation
종헌재 (2018) · Seoul National University Open Repository (Seoul National University)
Cappello, S. (2020) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8083
Xu, J., Wang, X., Jiang, H., Chen, Y., Wang, R., & Shu, Y. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001070
Djuzenova, C. S., Fischer, T., Katzer, A., Sisario, D., Korsa, T., Steußloff, G., Sukhorukov, V. L., & Flentje, M. (2020) · Research Square · doi:10.21203/rs.3.rs-121097/v1
Ras and Ras Signaling as a Therapeutic Target in Cancer
Sliker, B. H., & Campbell, P. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00006-2
Kozak, K., Świtaj, T., & Rutkowski, P. L. (2021) · Springer eBooks · doi:10.1007/978-3-030-64009-5_5 · Cited by 1
Gastrointestinal Toxicities of Targeted Therapy
Chowdhury, T., Sukari, A. W., & Nagasaka, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-67241-2.00013-6
Mechanisms of Toxicities Associated With Targeted Therapy
Abdallah, N. H., Nagasaka, M., & Sukari, A. W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-67241-2.00012-4
FGFR1 SER777 Mutasyonu ve Mesane Kanseri
Özgöz, A., Samli, A. C., Şamlı, M., Dinçel, D., İnce, Ü., & Şahin, A. (2021) · Kocaeli Üniversitesi Sağlık Bilimleri Dergisi · doi:10.30934/kusbed.799444
Translational research of combined anticancer therapies targeting the MAPK pathway
Huijberts, S. C. F. A. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/1019
Advances in Molecular Pathways and Targeted Therapy of Colon Cancer
(2022) · Journal of Contemporary Medical Practice · doi:10.53469/jcmp.2022.04(01).26
Targeted Treatments for Common Solid Tumors
PhD, E. V. (2018) · Wiley eBooks · doi:10.1002/9781119126843.ch6
Metadata
- Authors
- Samatar, A. A., & Poulikakos, P. I.
- Affiliations
- Tisch Cancer Institute (US)
- Corresponding author
- Poulikakos, Poulikos I.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-12
- Volume
- 13
- Issue
- 12
- Pages
- 928-942
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2050573392
- Cited by
- 1,163
- References
- 139
- Citations by year
- 2026: 47 · 2025: 77 · 2024: 106 · 2023: 100 · 2022: 102 · 2021: 134 · 2020: 119 · 2019: 105 · 2018: 117 · 2017: 101 · 2016: 108 · 2015: 45 · 2014: 2
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- RAF inhibitors, MEK inhibitors, ERK inhibitor, KRAS mutation, NRAS mutation, BRAF mutation, acquired drug resistance, intrinsic drug resistance, metastatic melanoma, targeted cancer therapy, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Delivery Systems, ras Proteins, MAP Kinase Signaling System, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.